The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).
 
Martin Hutchings
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Johnson & Johnson/Janssen; Roche; Takeda
Research Funding - Abbvie (Inst); Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Genmab (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Andrew Zelenetz
Honoraria - Curio Science; DAVA Pharmaceuticals; NCCN
Consulting or Advisory Role - Arvinas; AstraZeneca; BeiGene; BeOne; Genentech/Roche; Ipsen; Juno/Celgene/Bristol-Myers Squibb; Kite, a Gilead company; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Arvinas (Inst); BeiGene; Genentech/Roche; MEI Pharma; Pharmacyclics/Janssen (Inst)
Travel, Accommodations, Expenses - DAVA Pharmaceuticals; Ipsen
 
Jacob Haaber Christensen
Consulting or Advisory Role - Johnson & Johnson/Janssen; Takeda
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - Takeda (Inst); Takeda (Inst)
 
Almudena Cascales Hernandez
No Relationships to Disclose
 
Sarit Assouline
Consulting or Advisory Role - Abbvie; AstraZeneca; BeOne Medicines; Novartis; Roche
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
 
Luis Malpica Castillo
Research Funding - Dizal Pharma (Inst)
 
Shalin Kothari
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Foresight Diagnostics; Genentech; Incyte; Lilly
Research Funding - Bristol-Myers Squibb (Inst)
 
Dipenkumar Modi
Honoraria - Regeneron
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca (I); BMS (I); Bristol-Myers Squibb/Sanofi; Daiichi Sankyo/Lilly (I); Genmab
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genmab (Inst); Karyopharm Therapeutics (Inst)
Expert Testimony - AstraZeneca
 
Miguel Canales Albendea
No Relationships to Disclose
 
Damian Cubillas
No Relationships to Disclose
 
Alejandro Martin Garcia-Sancho
Honoraria - Abbvie; AstraZeneca; BeOne Medicines; Bristol-Myers Squibb; ideogen; Incyte; Janssen; Kite/Gilead; Kyowa Kirin; Lilly; Roche; SOBI; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genmab; GlaxoSmithKline; ideogen; Janssen; Kite/Gilead; Lilly; Miltenyi Biotec; Regeneron; Roche; SOBI
Research Funding - Kite/Gilead (Inst)
 
Catherine Diefenbach
Stock and Other Ownership Interests - Gilead Sciences; OverT Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Genmab; Janssen; Merck; MorphoSys; Regeneron; Seagen
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Merck (Inst); ProfoundBio (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
Expert Testimony - Jim Harmon
 
John Kuruvilla
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen; Kite/Gilead; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; Arvinas; Bristol-Myers Squibb; Gilead Sciences; Merck; Roche; Seagen
Research Funding - AstraZeneca; Merck; Roche
Other Relationship - Karyopharm Therapeutics
 
Paolo Caimi
Stock and Other Ownership Interests - Abcon Therapeutics; ContaX biologics
Consulting or Advisory Role - Abbvie; Autolus Therapeutics; Bristol-Myers Squibb/Celgene; Genentech; Genmab; Novartis; Recordati; SOBI; Synthekine
Research Funding - Abbvie; ADC Therapeutics; Genmab (Inst); Luminary Therapeutics; Recordati (Inst)
Patents, Royalties, Other Intellectual Property - XaTEC patent holder (I)
Travel, Accommodations, Expenses - Pint Pharma
(OPTIONAL) Uncompensated Relationships - Abcon Therapeutics; Luminary Therapeutics
 
Krish Patel
Consulting or Advisory Role - Abbvie; Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics; Arcus Biosciences (Inst); AstraZeneca; AstraZeneca (Inst); AvenCell (Inst); BeiGene; BeOne Medicines (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene/Juno (Inst); Caribou Biosciences; Caribou Biosciences (Inst); Century Therapeutics (Inst); Foresight Diagnostics (Inst); Genentech (Inst); Genentech/Roche; Genmab (Inst); Janssen (Inst); Kite, a Gilead company; Legend Biotech (Inst); Lilly; Loxo/Lilly (Inst); Lyell Immunopharma (Inst); Merck; Merck (Inst); Nurix; Pfizer; Sana Biotechnology; Sanofi (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Kite, a Gilead company
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Adicet Bio (Inst); Arvinas (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CRISPR Therapeutics (Inst); Fate Therapeutics (Inst); Indapta Therapeutics (Inst); Janssen (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Merck (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Sana Biotechnology (Inst); Treeline Biosciences (Inst); Xencor (Inst)
 
Sean Landrette
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas; Orphai Therapeutics
Patents, Royalties, Other Intellectual Property - Patents from Orhpai Therapeutics; Patents pending from arvinas
 
Xin Zhi
Employment - Arvinas
Stock and Other Ownership Interests - ARVINAS
 
Yuanyuan Zhang
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Roland Meier
Employment - Arvinas
 
Matthew Matasar
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Allogene Therapeutics; Arvinas; AstraZeneca; Epizyme; Genentech; Genmab; HUTCHMED; Incyte; Johnson & Johnson; Kite/Gilead; Merck; Novartis; Pfizer; Regeneron; Roche; Visionaries
Expert Testimony - Arnold & Porter; Recursion Pharmaceuticals